NASDAQ:ALZN Alzamend Neuro Q3 2025 Earnings Report $1.32 +0.06 (+4.76%) Closing price 04:00 PM EasternExtended Trading$1.34 +0.02 (+1.52%) As of 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alzamend Neuro EPS ResultsActual EPS-$1.71Consensus EPS -$2.61Beat/MissBeat by +$0.90One Year Ago EPSN/AAlzamend Neuro Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlzamend Neuro Announcement DetailsQuarterQ3 2025Date3/10/2025TimeAfter Market ClosesConference Call DateMonday, March 10, 2025Conference Call Time8:00AM ETUpcoming EarningsAlzamend Neuro's Q4 2026 earnings is estimated for Tuesday, July 28, 2026, based on past reporting schedules, with a conference call scheduled on Friday, July 31, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Alzamend Neuro Earnings HeadlinesAlzamend Neuro Announces Passing of Board Director38 minutes ago | tipranks.comAlzamend Neuro Insider Trading Activity | NASDAQ:ALZN | BenzingaMay 1, 2026 | benzinga.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.July 21 at 1:00 AM | Profits Run (Ad)Alzamend Neuro (ALZN) price target decreased by 10.71% to 25.50April 10, 2026 | msn.comAlzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General HospitalApril 7, 2026 | prnewswire.comAlzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain ...March 26, 2026 | finance.yahoo.comSee More Alzamend Neuro Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email. Email Address About Alzamend NeuroAlzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.View Alzamend Neuro ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3M's Redemption Arc: Can Q2 Earnings Change the Narrative?Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of EarningsConfidence Is Back, But Earnings Show the Consumer Is Being PickyIndustrial and Utility Giants Boost Dividends as Data Center Tailwinds BuildIREN’s $2.8 Billion AI Contract Haul Changes the Stock’s StoryBuy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesIs Domino's Stock Serving Up a Buying Opportunity? Upcoming Earnings Tesla (7/22/2026)Freeport-McMoRan (7/22/2026)Alphabet (7/22/2026)International Business Machines (7/22/2026)ServiceNow (7/22/2026)AT&T (7/22/2026)TE Connectivity (7/22/2026)Texas Instruments (7/22/2026)United Rentals (7/22/2026)Philip Morris International (7/22/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
